Tiziana Life Sciences completes patient enrollment for Milciclib, topline data by mid 2019

Tiziana Life Sciences has completed patient enrollment in the ongoing Phase 2a clinical a single-arm, repeated-dose, 6-month duration study of Milciclib for certain patients with unresectable or metastatic HCC, with the topline data from this multi-center trial, being conducted in Italy, Greece and Israel, will be available in the second quarter of 2019.

The company has earlier reported interim analysis data from the first 10 patients, following 6 months of treatment, showing that Milciclib (100 mg once daily; 4 days on/3 days off every 4 weeks defining each cycle) was well-tolerated in this HCC patient population.